Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the board of directors and management of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) on behalf of its investors [1][2]. Group 1: Investigation Details - The investigation aims to determine if the Verrica board has breached its fiduciary duties to shareholders [2]. - Shareholders are encouraged to participate in the investigation and can contact the Schall Law Firm for more information [2]. Group 2: Firm Background - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Group 1 - X-energy has filed for an initial public offering (IPO) in the United States, aiming to capitalize on increasing investor interest in nuclear power [1] - The company intends to list its Class A common stock on the Nasdaq under the ticker symbol "XE" [1] - Specific details regarding the number of shares to be offered and the price range have not been disclosed [2]

Core Viewpoint - EyePoint Inc has filed a lawsuit against Ocular Therapeutix, alleging the spread of false or misleading information regarding EyePoint's lead experimental eye drug, Duravyu [1][2]. Group 1: Legal Actions - The lawsuit was filed in Middlesex County Superior Court, Massachusetts, accusing Ocular Therapeutix of defamation, commercial disparagement, and violations of consumer protection law [2][3]. - EyePoint is seeking a court order to stop Ocular Therapeutix from making the alleged false statements, demand a public retraction, and claim monetary damages and legal fees [3]. Group 2: Product Development - EyePoint's Duravyu is currently undergoing late-stage studies for wet age-related macular degeneration (wet AMD) and diabetic macular edema, with data for wet AMD expected to be available by mid-2026 [4]. - Ocular Therapeutix's leading drug, Axpaxli, recently met the main goal of a key late-stage trial, demonstrating its effectiveness in helping patients with wet AMD maintain vision compared to Regeneron's Eylea [4].

Sio Capital Management disclosed a new position in Organon (OGN 3.91%) on February 17, 2026, acquiring 3,421,765 shares worth $24.53 million at quarter’s end.What happenedAccording to a filing with the U.S. Securities and Exchange Commission dated February 17, 2026, Sio Capital Management established a new position in Organon (OGN 3.91%), purchasing 3,421,765 shares. The reported position value at quarter-end increased by $24.53 million as a result of the purchase.What else to knowThis is a new position for ...

Core Viewpoint - Rosen Law Firm is urging investors of Beyond Meat, Inc. (NASDAQ: BYND) to participate in a class action lawsuit due to allegations of misleading statements regarding the company's business operations and financial health [1][2]. Group 1: Allegations and Lawsuit Details - The class action lawsuit pertains to securities purchased between February 27, 2025, and November 11, 2025, claiming that Beyond Meat made false and misleading statements [1][3]. - Allegations include that the book value of certain long-lived assets exceeded their fair value, indicating a likely material, non-cash impairment charge, which could affect the company's ability to file timely reports with the SEC [3]. - The lawsuit asserts that these misleading statements caused investors to suffer damages when the true details became public [3]. Group 2: Participation and Legal Representation - Shareholders interested in serving as lead plaintiffs must file motions by March 24, 2026, and can choose to remain absent class members without participating in the case [4]. - Rosen Law Firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless they recover losses [5][6]. - The firm has a strong track record, having recovered over $1 billion for shareholders since its inception [6].

Core Insights - Bristol Myers Squibb has received expanded approvals for Opdivo® (nivolumab) in the treatment of classical Hodgkin lymphoma in the U.S. and by the European Medicines Agency (EMA) [1] Group 1 - The approval marks a significant transformation in the treatment paradigm for classical Hodgkin lymphoma, indicating a shift towards more effective therapeutic options [1] - Opdivo® is now recognized for its potential to improve patient outcomes in this specific cancer type, reflecting advancements in immunotherapy [1] - The expanded indication is expected to enhance the company's market position and drive revenue growth in the oncology segment [1]

Core Viewpoint - Pfizer Inc. recommends shareholders reject the unsolicited mini-tender offer from Tutanota LLC, which proposes to purchase up to 1 million shares at $32.00 per share, as the offer price is below the market value and contingent on conditions that may not be met [1][2][3]. Offer Details - Tutanota's offer is for approximately 0.02% of Pfizer's outstanding shares as of March 9, 2026, and is conditioned on Pfizer's stock price exceeding $32.00 on the last trading day before the offer expires [1][2]. - The offer is set to expire at 5:00 p.m. on April 13, 2026, but Tutanota may extend this period at its discretion [2][6]. Shareholder Guidance - Pfizer advises shareholders not to tender their shares due to the conditions attached to Tutanota's offer, including the requirement for Tutanota to secure financing, which it currently lacks [2][6]. - Shareholders who have already tendered their shares can withdraw them prior to the expiration date [2][6]. Regulatory Context - Mini-tender offers like Tutanota's seek to acquire less than 5% of a company's shares, allowing them to bypass many SEC disclosure requirements, which may result in less protection for investors [4][5]. - The SEC has warned that some mini-tender offers at below-market prices may catch investors off guard if they do not compare the offer price to the current market price [5].

Core Insights - Eli Lilly (LLY) announced positive results from a late-stage study of its weight-loss drug retatrutide for adults with type II diabetes, achieving significant reductions in A1C and body weight [1][2][3] Group 1: Study Results - The TRANSCEND-T2D-1 study met its primary endpoint, showing A1C reductions of 1.7% to 2% for retatrutide compared to 0.8% for placebo under the efficacy estimand [2] - Patients taking retatrutide lost up to 16.8% of their body weight, while the placebo group lost 2.5% under the efficacy estimand [3] - The study evaluated three doses of retatrutide (4 mg, 9 mg, and 12 mg) over 40 weeks against a placebo [1] Group 2: Drug Mechanism and Competitors - Retatrutide activates three hormone receptors: GLP-1, GIP, and glucagon, compared to Eli Lilly's Zepbound, which targets GLP-1 and GIP, and Novo Nordisk's Wegovy, which activates only GLP-1 [5] - The obesity market is competitive, with Eli Lilly and Novo Nordisk leading in injectable therapies, while both companies are also racing to introduce oral weight-loss pills [9][10] Group 3: Future Developments - Eli Lilly is conducting multiple late-stage studies for retatrutide across various cardiometabolic conditions, with results from additional studies expected later this year [4] - The FDA is currently reviewing Eli Lilly's obesity pill orforglipron, with a decision anticipated soon [10]

Core Insights - Bristol Myers (BMY) has received FDA approval for Sotyktu, expanding its label to include adults with active psoriatic arthritis (PsA), which enhances the drug's commercial profile and lifecycle potential [1][4] - Sotyktu is the first TYK2 inhibitor approved for PsA, offering a differentiated oral therapy in a market traditionally dominated by injectable biologics [2][4] - The label expansion strengthens Bristol Myers' immunology franchise and diversifies its revenue streams beyond oncology, addressing both skin and joint manifestations of psoriatic arthritis [3][10] Market Dynamics - The PsA market is highly competitive, with established biologics and oral agents already present, making commercial execution critical for Sotyktu [4][10] - Sotyktu's sales reached $291 million in 2025, reflecting a 19% increase from 2024, and it is also being evaluated for lupus and Sjogren's Disease [5] Competitive Landscape - Sotyktu faces competition from Amgen's Otezla and Novartis' Cosentyx, both of which have established market presence and multiple indications [7][8][10] - Cosentyx generated $6.7 billion in revenues for Novartis in 2025, marking an 8% growth from 2024, highlighting the competitive pressure in the market [9] Financial Performance - Bristol Myers shares have declined by 4.8% over the past year, contrasting with the industry's growth of 11.2% [13] - The company is trading at a price/earnings ratio of 9.34x forward earnings, which is lower than the large-cap pharma industry's average of 16.92x [14] - The Zacks Consensus Estimate for 2026 EPS has increased to $6.26 from $6.15, indicating positive revisions in earnings expectations [16]

Robbins LLP Reminds Inovio Pharmaceuticals, Inc. Stockholders of the Pending Class Action Against INO and Urges Harmed Stockholders to Seek More Information Share SAN DIEGO--(BUSINESS WIRE)-- Robbins LLPreminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization ...